Skip Ribbon Commands
Skip to main content
Sign In



Terumo BCT Announces Enrollment of the First Patient in Its U.S. Clinical Trial Designed to Study Platelets Treated With the Mirasol® Pathogen Reduction Technology (PRT) System

Collaborative Global Effort to Advance Blood Safety Moves Forward Across Ghana

Terumo BCT's Spectra Optia® Apheresis System Is the First and Only Device on the European Market Indicated to Treat Guillain-Barré Syndrome and Myasthenia Gravis using Therapeutic Plasma Exchange

Announcing Our Strategic Collaboration With Cognate BioServices

Read About Our Exclusive Distribution Agreement With B Medical Systems

We’ve Been Awarded $1.9 Million From the United States Government to Support Development of Freeze-Dried Plasma